This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Transdermal Drug Patches To 2018 - Products, Indications, Markets And Forecasts

NEW YORK, March 19, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Transdermal Drug Patches to 2018 - Products, Indications, Markets and Forecasts

Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Growth in demand for drug patches is being driven by several factors – factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2018.

  • Analyzes and evaluates prescription skin patch products and assesses risks and market potential
  • Analyzes patch designs, technologies and patch development issues
  • Provides assessments of transdermal drug patch products in two dozen key market segments
  • Provides market data and forecasts to 2018
  • Profiles patch manufacturers, their product development activities and strategies


Summary of Contents


Executive Summary


The Market Opportunity

Transdermal Drug Delivery Dynamics

Demand Drivers

Competitive Landscape

Factors Limiting Growth

Pharmacokinetics & Dosage Forms

Patch Manufacturing Dynamics

Patch Manufacturing Company Profiles


Product Analysis – FDA-Approved Drugs Delivered via Transdermal Patches






CNS Stimulants

Cholinesterase Inhibitors

Dopamine Agonists

Hormone Replacement

Hypotensive Agents

Local Anesthetics


Opioid Analgesics




Market Analysis – Transdermal Drug Patch Therapeutics






Hormone Replacement Therapy


Motion Sickness



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs